Brentuximab vedotin with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma: A Children’s Oncology Group, Single-arm, Phase 1 / 2 Trial.

BACKGROUND: Patients with primary refractory Hodgkin lymphoma or early relapse have a poor prognosis. Although many salvage regimens have been developed, there is no standard of care. METHODS. Children’s Oncology Group protocol AHOD1221 (NCT01780662) tested Brentuximab vedotin with gemcitabine in ch...

詳細記述

保存先:
書誌詳細
出版年:Lancet Oncol
主要な著者: Cole, Peter D., McCarten, Kathleen M., Pei, Qinglin, Spira, Menachem, Metzger, Monika L., Drachtman, Richard A., Horton, Terzah M., Bush, Rizvan, Blaney, Susan M., Weigel, Brenda J., Kelly, Kara M.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487196/
https://ncbi.nlm.nih.gov/pubmed/30122620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30426-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料